Poseida Therapeutics, Inc. (PSTX) Tops Q1 EPS by 16c

Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q1 EPS of ($0.45), $0.16 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $10.34 million versus the consensus estimate of $1.57 million.

For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Morgan Stanley more than doubles Lenovo price target on AI-driven growth
• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance